AscellaHealth CEO, Dea Belazi, Honored as a 2024 PM360 Elite 100 Winner

Dea Belazi

AscellaHealth, a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions, is pleased to announce Dea Belazi, CEO and co-founder, AscellaHealth, is recognized as a PM360 Elite 100 Winner as a Transformational Leader in the tenth annual Elite 100. Belazi will be honored at the ELITE 100 Awards event on June 18th in New York City. All of the 100 winners are profiled in PM360’s May 2024 issue.

“This honor truly belongs to the entire AscellaHealth team in recognition of their expertise, dedication and ongoing work that enables patients with complex, chronic conditions to access specialty pharmaceuticals and novel therapies that enhance clinical outcomes,” says Belazi. “It is gratifying to lead a group of talented professionals who share my commitment to healthcare transformation and improving the processes for getting critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma.”

The ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people and teams in the healthcare and life sciences industries based on their career accomplishments. Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry. Nominees for the award are evaluated based on their accomplishments; testimonials from their bosses, clients, and colleagues; and supporting evidence that reflects the impact of their efforts.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”